Press release
Global Acute Myeloid Leukemia Clinical Trial Activity Surges as 110+ Emerging Therapies Gain Momentum, Reports DelveInsight
Acute Myeloid Leukemia Clinical Trial
The Acute Myeloid Leukemia Pipeline Insight 2025 report offers an extensive commercial and clinical review of AML pipeline products, spanning preclinical stages to marketed therapies. It details each drug candidate's mechanism of action, clinical data, regulatory milestones (including NDA status), and development activities-covering technologies, collaborations, acquisitions, funding, and other product-specific insights.
The report delivers a comprehensive overview of the current clinical landscape and future growth prospects across the Acute Myeloid Leukemia market.
Request for sample report - https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Acute Myeloid Leukemia Pipeline Report
• A strong global effort is underway to advance novel Acute Myeloid Leukemia therapies, with notable progress achieved in recent years.
• Leading companies in the Acute Myeloid Leukemia therapeutic landscape include SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, and others.
• Key emerging Acute Myeloid Leukemia therapies such as GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab + azacitidine, and Uproleselan - are advancing through the clinical pipeline and expected to significantly influence the Acute Myeloid Leukemia treatment landscape.
Recent Acute Myeloid Leukemia Clinical & Regulatory Developments
• April 2025: CERo Therapeutics announced that the Colorado Blood Cancer Institute (CBCI) at SCRI will lead the Phase I trial of CER-1236 for relapsed/refractory AML and TP53-mutated AML. Patient enrollment is underway, with dosing expected by June.
• February 2025: Moleculin Biotech secured approval from Ukraine's Ministry of Health to begin patient enrollment for its global Phase III MIRACLE trial evaluating annamycin + cytarabine in relapsed/refractory AML.
• January 2025: The FDA granted Fast Track Designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody for AML. The therapy already holds orphan drug status for AML and a separate Fast Track designation for head and neck cancers.
• October 2024: Qurient Co. Ltd. initiated a Phase I study for adrixetinib (Q702) as monotherapy and in combination with venetoclax + azacitidine for relapsed/refractory AML.
• September 2024: Rigel Pharmaceuticals reported dosing the first patient in a Phase Ib/II study evaluating REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax in mIDH1 AML.
• May 2024: GlycoMimetics released key Phase III findings for uproleselan, studied with MEC or FAI chemotherapy in relapsed/refractory AML patients.
Get a Free Sample PDF Report to know more about Acute Myeloid Leukemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute Myeloid Leukemia (AML): Overview
AML is an aggressive hematologic malignancy characterized by the rapid accumulation of immature myeloid cells in the bone marrow, disrupting the production of healthy blood cells, including red cells, white cells, and platelets.
Emerging Acute Myeloid Leukemia Drugs Across Clinical Phases
• GNC 035 - SystImmune
• JSP 191 - Jasper Therapeutics
• ONC201 - Chimerix
• AK117 - Akeso Biopharma
• Tamibarotene - Syros Pharmaceuticals
• TCB008 - TC Biopharm
• Elzonris - Stemline Therapeutics
• Orca T - Orca Bio
• Magrolimab + azacitidine - Gilead Sciences
• Uproleselan - GlycoMimetics
Acute Myeloid Leukemia Routes of Administration (RoA) Covered
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Acute Myeloid Leukemia Molecule Types Featured
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies
Acute Myeloid Leukemia Therapeutic Assessment Includes
• Evaluation by product type
• Assessment by development stage (preclinical-Phase III)
• Categorization by route of administration
• Classification by molecule type
• Status of active, dormant, and discontinued programs
Further Acute Myeloid Leukemia product details are provided in the report. Download the Acute Myeloid Leukemia pipeline report to learn more about the emerging Acute Myeloid Leukemia therapies - https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's report covers 110+ investigational products, including late-stage, mid-stage, early-stage candidates, discovery programs, and discontinued therapies.
Key Companies in the Acute Myeloid Leukemia Therapeutics Market
Major Acute Myeloid Leukemia Companies include GlycoMimetics, BioSight, Merck Sharp & Dohme, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience, Astex Pharmaceuticals, Karyopharm, Mesoblast, SELLAS Life Sciences, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Cullinan Therapeutics, Aptose Biosciences, Celgene, and others.
Acute Myeloid Leukemia Market Drivers
• Increasing global incidence of AML
• Advances in molecular biology and targeted drug development
• Growing elderly population
Acute Myeloid Leukemia Market Challenges
• High treatment costs
• Severe side effects associated with AML therapies
• Limited accessibility in some regions
Download Sample PDF Report to know more about Acute Myeloid Leukemia drugs and therapies
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Acute Myeloid Leukemia Pipeline Insight Report
• Coverage: Global
• Key Acute Myeloid Leukemia Companies: SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, and others
• Key Acute Myeloid Leukemia Therapies: GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, and others
• Acute Myeloid Leukemia Therapeutic Assessment: Acute Myeloid Leukemia current marketed and Acute Myeloid Leukemia emerging therapies
• Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia market drivers and Acute Myeloid Leukemia market barriers
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Acute Myeloid Leukemia Clinical Trial Activity Surges as 110+ Emerging Therapies Gain Momentum, Reports DelveInsight here
News-ID: 4278983 • Views: …
More Releases from DelveInsight Business Research
Familial Chylomicronemia Syndrome Market to Expand Significantly by 2034, States …
DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome…
Generalized Anxiety Disorder Pipeline 2025: Therapies, MOA Insights, and Key Cli …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Generalized Anxiety Disorder pipeline constitutes 12+ key companies continuously working towards developing 15+ Generalized Anxiety Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Generalized Anxiety Disorder Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Generalized Anxiety…
Primary Mitochondrial Myopathies Pipeline 2025: MOA, ROA, FDA-Approved Drugs, an …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Mitochondrial Myopathies pipeline constitutes 4+ key companies continuously working towards developing 4+ Primary Mitochondrial Myopathies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Primary Mitochondrial Myopathies Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Mitochondrial…
Chlamydia Infections Pipeline 2025: Therapies Under Investigation, Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chlamydia Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Chlamydia Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Chlamydia Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
More Releases for Acute
Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,…
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but…
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to…
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth…
